Meeder Asset Management’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-376
Closed -$1.74K 1570
2018
Q2
$1.74K Buy
376
+301
+401% +$5.03K ﹤0.01% 1435
2018
Q1
$2K Hold
75
﹤0.01% 1370
2017
Q4
$2K Buy
75
+39
+108% +$1.73K ﹤0.01% 1483
2017
Q3
$2K Buy
36
+14
+64% +$873 ﹤0.01% 1443
2017
Q2
$2K Buy
22
+7
+47% +$451 ﹤0.01% 1391
2017
Q1
$1K Sell
15
-71
-83% -$9.64K ﹤0.01% 1497
2016
Q4
$13K Buy
+86
New +$20.1K ﹤0.01% 708

Other funds holding CRDF

Meeder Asset Management's CRDF Position: Q3 2018 in Review

Meeder Asset Management sold out of Cardiff Oncology (CRDF) in Q3 2018, closing a stake of 376 shares — an estimated $1.74K sold.

Meeder Asset Management first reported a position in CRDF in Q4 2016 and held it in 7 quarters. The position peaked at $13K in Q4 2016. 33 funds tracked by Wall St. Rank hold CRDF as of Q3 2018.

  • Meeder Asset Management reported no remaining Cardiff Oncology position as of Q3 2018 after selling out during the quarter.
  • Meeder Asset Management sold 376 Cardiff Oncology shares in Q3 2018, an estimated $1.74K.
  • Meeder Asset Management first reported a position in Cardiff Oncology in Q4 2016 and held it in 7 quarters.
  • Meeder Asset Management's Cardiff Oncology position peaked at $13K in Q4 2016.
  • 33 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2018.

Based on Meeder Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.